The plasma dopamine (DA) level has scarcely been investigated in acute cerebrovascular diseases (CVD), although sympathetic hyperactivity has been well demonstrated. We measured the plasma DA and norepinephrine in acute CVD, and examined whether or not the plasma DA level had any significant relationship to sympathetic nervous function or clinical prognosis in acute CVD. The subjects comprised 12 patients (74 ± 11 yo, mean ± SD) with intracerebral hemorrhage (ICH) and 18 (63 ± 9 yo) with cerebral infarction (CI) within 3 days after onset. Healthy controls adjusted for age to each group were also included in the study (25 for ICH and 36 for CI). Based on observations for 3 months, the patients were divided into two groups : surviving and non-surviving groups. The numbers in the surviving and non-surving groups were, respectively, 7 and 5 cases in the ICH group, and 5 and 13 cases in the CI group.
(1) Plasma catecholamines : The DA level in acute ICH was significantly higher compared to that in the control (52 ± 18 pg/ml vs. 10 ± 1; mean ± SE, p <0.005). The DA level in acute CI was also higher than that in the control (22.0 ± 6.9 vs, 9.7 ± 0.9, p < 0.05). The NE level in acute ICH was higher compared to that in the control (1240 ± 252 vs. 337 ± 31, p <0.0005). The NE level in acute CI was higher than that in the control (570 ± 126 vs. 327 ± 24, p <0.05).
(2) DA vs. norepinephrine : The relationship between the DA and norepinephrine levels displayed significantly positive correlations in both ICH (r = 0.905, p =0.0001) and CI (r = 0.868, p =0.0001).
(3) DA vs. clinical prognosis : Among patients with ICH, the plasma DA level tended to be lower in the surviving group (28 ± 9) as compared to the non-surviving group (86 ± 38). Among patients with CI, the DA level was significantly lower in the surviving group (12 ± 3) than in the non-surviving group (49 ± 20) (p < 0.05).
In conclusion, the above data indicate that an increased plasma DA in acute CVD is a parameter of sympathetic nervous function and may be useful for predicting the clinical prognosis in acute CVD.
View full abstract